Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group.
about
Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world.Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis.The Psoriatic Arthritis Impact of Disease 12-item questionnaire: equivalence, reliability, validity, and feasibility of the touch-screen administration versus the paper-and-pencil version.The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment.Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials.A review of disease activity measures for psoriatic arthritis: what is the best approach?Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study.Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare.Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity.High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission.
P2860
Q33747197-B3DE0C1E-4D21-45F4-8582-B78B24973D94Q33876826-2338BBBA-60A6-4864-B1E9-39FE52F56D35Q36833558-72D6EE82-73D9-4C6F-9DC7-453854DB1688Q38191200-7803D450-2F32-4005-A870-8ADC09220EE6Q38211315-617169AD-D405-4FAE-A80F-A25A35338AD9Q38236514-336F838C-C8E4-4C3C-AC76-0B1133C5ED08Q38947002-26E4816F-C66D-4B2A-B2DD-C4E22275D785Q46893265-A1212FC4-2DF0-48E2-BB1F-106BA3AD518FQ50318004-739C9234-BAA2-402E-B5BE-2EE51D679418Q51162191-7E36BD29-0631-46C0-A79E-B32B76A0C5A5Q54443616-6CBE6FC6-6199-4AB0-84AA-DD6B262ED3F6
P2860
Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of a disease sever ...... 10 PsA special interest group.
@en
Development of a disease sever ...... 10 PsA special interest group.
@en-gb
Development of a disease severity and responder index for psoriatic arthritis
@nl
type
label
Development of a disease sever ...... 10 PsA special interest group.
@en
Development of a disease sever ...... 10 PsA special interest group.
@en-gb
Development of a disease severity and responder index for psoriatic arthritis
@nl
prefLabel
Development of a disease sever ...... 10 PsA special interest group.
@en
Development of a disease sever ...... 10 PsA special interest group.
@en-gb
Development of a disease severity and responder index for psoriatic arthritis
@nl
P2093
P50
P356
P1476
Development of a disease sever ...... 10 PsA special interest group.
@en
P2093
Aizad Mumtaz
Gerald G Krueger
Kristina Callis-Duffin
Neil J McHugh
Oliver FitzGerald
Philip J Mease
Vibeke Strand
P304
P356
10.3899/JRHEUM.110278
P407
P577
2011-07-01T00:00:00Z